Transgene Biotek Limited has submitted a formal intimation to the Bombay Stock Exchange Limited regarding the non-applicability of SEBI Regulation 32(1) for the quarter ended June 30, 2026.
The disclosure is made pursuant to SEBI circular CIR/CFD/CMD1/162/2019 dated December 24, 2019, and its amendments, which require listed entities to submit a Statement of Deviation or Variation for proceeds from public issues, rights issues, preferential issues, or Qualified Institutions Placements (QIP).
The company explicitly states that during the reporting quarter (ended June 30, 2026), there were no public issues, rights issues, preferential issues, or any similar capital-raising activities. Consequently, the requirement to file a Statement of Deviation or Variation under Regulation 32(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 does not apply to the company for this period.
An additional operational note mentions that the company was unable to file this intimation under XBRL mode because the form does not allow for NIL entries.
The letter is signed by Dr. K Koteswara Rao in his capacity as Chairman & Managing Director of Transgene Biotek Limited.